Literature DB >> 8480725

Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A.

S B Hanauer1, M B Smith.   

Abstract

Fistulas complicating Crohn's disease often are refractory to medical management. Immunosuppressive therapy is sometimes effective but requires several months before efficacy can be determined. We treated five patients with Crohn's disease complicated by chronic draining fistulas unresponsive to previous surgery, steroids, antibiotics, total parenteral nutrition, 6-mercaptopurine, or azathioprine with continuous infusion cyclosporin A (CyA). The five patients had a total of 12 fistulas (five enterovaginal, three perianal, three enterocutaneous, one enterovesical). CyA was administered initially at 4 mg/kg/day for 6-10 days, after which oral dosing was begun at 8 mg/kg/day and adjusted to maintain trough serum levels of 100-200 ng/ml. All fistulas responded to CyA infusion with decreased drainage and with improvement in both perifistular inflammation and patient comfort. Complete resolution of drainage was seen in 10 of the 12 fistulas. Initial response was seen after a mean of 3.6 days (range, 2-5 days) with complete cessation of drainage in the 10 fistulas after a mean of 7.9 days (range, 3-28 days). Therapy was continued for a mean of 6.2 months (range, 1.5-18 months). Relapse was seen in two perianal fistulas (3 wk and 7 months) and in two enterovaginal fistulas (1 and 2 months). Two of these recurrences corresponded to lowered serum levels of CyA. An enterocutaneous fistula also recurred after 2.5 months, associated with a distal stricture that required resection. Side effects were minor except for a mycotic aneurysm in one patient which occurred after 7 months of treatment. Intravenous CyA may prove to be a useful agent in the initial management of refractory Crohn's disease fistulas, although relapse as serum levels are lowered and infectious complications are limiting factors for long-term use as a single agent.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8480725

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  27 in total

Review 1.  Managing Perianal Crohn’s Disease.

Authors:  Dawn M Wiese; David A Schwartz
Journal:  Curr Gastroenterol Rep       Date:  2012-04

Review 2.  Management of perianal fistulas in Crohn's disease: an up-to-date review.

Authors:  Manuela Marzo; Carla Felice; Daniela Pugliese; Gianluca Andrisani; Giammarco Mocci; Alessandro Armuzzi; Luisa Guidi
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

3.  Effect of liver transplantation on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  Igor Dvorchik; Michael Subotin; A Jake Demetris; John J Fung; Thomas E Starzl; Samuel Wieand; Kareem M Abu-Elmagd
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

4.  Pharmacokinetics of cyclosporin microemulsion in patients with inflammatory bowel disease.

Authors:  M Latteri; G Angeloni; N G Silveri; R Manna; G Gasbarrini; P Navarra
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Pharmacological Approach to the Management of Crohn's Disease Patients with Perianal Disease.

Authors:  Fernando Bermejo; Iván Guerra; Alicia Algaba; Antonio López-Sanromán
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

6.  Immunomodulator Therapy in Inflammatory Bowel Disease.

Authors:  Peter E. Legnani; Asher Kornbluth
Journal:  Curr Treat Options Gastroenterol       Date:  2001-06

Review 7.  Multidisciplinary and evidence-based management of fistulizing perianal Crohn's disease.

Authors:  Ricardo Sordo-Mejia; Wolfgang B Gaertner
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15

8.  Treatment of complex perianal fistulas in Crohn disease: infliximab, surgery or combined approach.

Authors:  Guido Sciaudone; Crescenzo Di Stazio; Paolo Limongelli; Ilaria Guadagni; Gianluca Pellino; Gabriele Riegler; Paolo Coscione; Francesco Selvaggi
Journal:  Can J Surg       Date:  2010-10       Impact factor: 2.089

9.  Molecular evidence for two forms of Crohn disease.

Authors:  E C Gilberts; A J Greenstein; P Katsel; N Harpaz; R J Greenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 10.  Anti-TNF strategies in stenosing and fistulizing Crohn's disease.

Authors:  Martin H Holtmann; Markus F Neurath
Journal:  Int J Colorectal Dis       Date:  2004-09-30       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.